HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives
RSC Advances · 2026 · 16 (4) · 3430-3442
DOI: 10.1039/d5ra09034b ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Abdallah E Abdallah. Beteiligte Einrichtung: Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University Cairo 11884 Egypt abdulla_emara@azhar.ed…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
In an attempt to collect clinical data about HDAC inhibitors as very significant anticancer drugs, we aimed to compare data and reveal the impact of the structural features to help – develop better cancer therapy.
Autor:innen und Institutionen
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University Cairo 11884 Egypt abdulla_emara@azhar.edu.eg.
ORCID-Profile: Abdallah E Abdallah
Zitieren
APA
Abdallah, A. E. (2026). HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives. RSC Advances, 16(4), 3430-3442. https://doi.org/10.1039/d5ra09034b
Vancouver
Abdallah AE. HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives. RSC Advances. 2026;16(4):3430-3442. doi:10.1039/d5ra09034b
BibTeX
@article{Abdallah2026,
author = {Abdallah, Abdallah E},
title = {HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives},
journal = {RSC Advances},
year = {2026},
volume = {16},
number = {4},
pages = {3430--3442},
doi = {10.1039/d5ra09034b}
}
EUVIMED